Black Diamond Therapeutics, BDTX-1535
Black Diamond reports encouraging Phase 2 data for BDTX-1535
Black Diamond Therapeutics (NASDAQ:BDTX) reported encouraging Phase 2 data for its drug candidate BDTX-1535 in the treatment of patients with recurrent EGFR-mutant non-small cell lung cancer, or NSCLC.
Black Diamond Therapeutics Gains On Positive Phase 2 Data For BDTX-1535 In Patients With NSCLC
Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or
Black Diamond Therapeutics Shares Jump on Positive Data for Cancer Treatment
Shares in Black Diamond Therapeutics rose after the company outlined positive initial data from Phase 2 trials of BDTX-1535, an oral cancer treatment. Shares were up 46% in premarket trading at $6.94.
Black Diamond Therapeutics Inc (BDTX) Stock’s 0.98% Increase This Year: What’s the Story?
Raymond James has recently initiated Black Diamond Therapeutics Inc (BDTX) stock to Outperform rating, as announced on July 31, 2024, according to Finviz. Earlier, on July 14, 2023, Piper Sandler had initiated the stock to Overweight.
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to disclose initial phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC on Monday,
FierceBiotech16h
Black Diamond, Ideaya entertain registrational trial ideas as cancer drugs show midstage promise
Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after ...
ENDPOINTS NEWS19h
Black Di­a­mond treads wa­ter on small snap­shot of Phase 2 lung can­cer da­ta
Black Diamond Therapeutics’ stock price $BDTX jumped more than 15% premarket Monday morning after the company reported its ...
Business Insider6d
Buy Rating Affirmed for Black Diamond Therapeutics Amid Promising NSCLC Treatment Advances
Black Diamond Therapeutics (BDTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating ...
Officials respond to ‘Black Diamond’ fire southwest of Thedford
Thedford Volunteer Fire and Rescue responded to a report of a “Black Diamond” fire southwest of Thedford Saturday.
Enumclaw Courier-Herald on MSN6d
Oakpointe’s developments are 20% completed. What’s next? Recreation
Ten Trails and Lawson Hills neighborhoods developer Oakpointe is asking the Black Diamond City Council to consider recreation ...
Mexico News Daily2d
Emma Coronel, wife of ‘El Chapo’ Guzmán, to model at Milan Fashion Week
Emma Coronel, a former beauty queen, was released from prison a year ago, and will now be a runway model at Milan Fashion ...
Charleston Gazette-Mail3d
Girl Scouts to celebrate 100th year at Family Fall Fest
The Girl Scouts of Black Diamond Council will celebrate 100 years of memories at a Family Fall Fest from 10 a.m. until 2 p.m.
‘The Poky Dot’ building put up for sale
According to a listing from real estate group Black Diamond Realty, “The Poky Dot” building located at 1111 Fairmont Avenue ...
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) reported initial Phase 2 data of BDTX-1535. The data demonstrated encouraging ...